BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
| Autor: | Ma, Yuxiang *, Huang, Yan *, Zhao, Yuanyuan *, Zhao, Shen *, Xue, Jinhui *, Yang, Yunpeng *, Fang, Wenfeng *, Guo, Ye, Han, Yaqian, Yang, Kunyu, Li, Yongsheng, Yang, Jun, Fu, Zhenming, Chen, Gang, Chen, Likun, Zhou, Ningning, Zhou, Ting, Zhang, Yaxiong, Zhou, Huaqiang, Liu, Qianwen, Zhu, Yi, Zhu, Hai, Xiao, Sa, Zhang, Li †, **, Zhao, Hongyun †, * |
|---|---|
| Zdroj: | In The Lancet Oncology July 2024 25(7):901-911 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|